INmune Bio (NASDAQ:INMB) Posts Earnings Results, Beats Expectations By $0.12 EPS

INmune Bio (NASDAQ:INMBGet Rating) announced its quarterly earnings data on Wednesday. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.12, Fidelity Earnings reports. INmune Bio had a negative net margin of 9,233.15% and a negative return on equity of 40.39%. During the same period last year, the firm earned ($0.44) EPS.

INmune Bio Trading Up 0.8 %

Shares of INmune Bio stock traded up $0.08 during trading on Friday, hitting $10.39. The company’s stock had a trading volume of 83,854 shares, compared to its average volume of 131,337. The company has a debt-to-equity ratio of 0.19, a current ratio of 23.89 and a quick ratio of 23.89. The stock has a market cap of $186.46 million, a price-to-earnings ratio of -5.56 and a beta of 1.91. The stock has a 50-day moving average price of $8.57 and a two-hundred day moving average price of $8.39. INmune Bio has a 52 week low of $4.63 and a 52 week high of $30.37.

Wall Street Analyst Weigh In

INMB has been the topic of several research reports. B. Riley downgraded shares of INmune Bio from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $14.00 to $7.00 in a report on Tuesday, May 24th. Maxim Group initiated coverage on shares of INmune Bio in a research note on Friday, May 6th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, BTIG Research decreased their price target on shares of INmune Bio from $31.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, May 24th.

Insider Buying and Selling at INmune Bio

In related news, CFO David J. Moss acquired 7,700 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were bought at an average price of $6.27 per share, with a total value of $48,279.00. Following the transaction, the chief financial officer now directly owns 1,244,651 shares of the company’s stock, valued at $7,803,961.77. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CFO David J. Moss acquired 7,700 shares of the firm’s stock in a transaction on Thursday, May 26th. The stock was purchased at an average price of $6.27 per share, for a total transaction of $48,279.00. Following the purchase, the chief financial officer now owns 1,244,651 shares in the company, valued at approximately $7,803,961.77. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Raymond Joseph Tesi acquired 6,300 shares of the firm’s stock in a transaction on Thursday, May 26th. The stock was purchased at an average price of $6.41 per share, with a total value of $40,383.00. Following the purchase, the chief executive officer now owns 1,520,698 shares in the company, valued at approximately $9,747,674.18. The disclosure for this purchase can be found here. Insiders own 34.20% of the company’s stock.

Hedge Funds Weigh In On INmune Bio

Several institutional investors have recently bought and sold shares of INMB. Vanguard Group Inc. lifted its position in shares of INmune Bio by 8.3% during the 1st quarter. Vanguard Group Inc. now owns 553,638 shares of the company’s stock valued at $4,661,000 after buying an additional 42,609 shares during the last quarter. Royal Bank of Canada lifted its position in shares of INmune Bio by 17.2% during the 1st quarter. Royal Bank of Canada now owns 51,606 shares of the company’s stock valued at $434,000 after buying an additional 7,575 shares during the last quarter. Finally, State Street Corp lifted its position in shares of INmune Bio by 11.4% during the 1st quarter. State Street Corp now owns 37,663 shares of the company’s stock valued at $317,000 after buying an additional 3,847 shares during the last quarter. Hedge funds and other institutional investors own 13.91% of the company’s stock.

INmune Bio Company Profile

(Get Rating)

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease.

Recommended Stories

Earnings History for INmune Bio (NASDAQ:INMB)

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.